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Purpose
Localized scleroderma (LS) is a chronic inflammatory
and fibrosing skin disease, more common in children.
We present baseline data on the juvenile LS (jLS) cohort
from the CARRAnet observational registry of pediatric
rheumatologic disorders.
Methods
We performed a cross-sectional baseline analysis of reg-
istry data for jLS.
Results
Data were available on 44 children. 81.8% were female
and 88.6% were Caucasian, of which 13.6% were Latino.
Mean age at onset was 8.2 years (± 4.0), yet first evalua-
tion by a pediatric rheumatologist was 9.9 years (± 4.2).
Reported subtypes were: 34 linear scleroderma (LiScl: 25
trunk/limbs, 9 face/neck), 7 with circumscribed mor-
phea (CM: 5 deep, 2 superficial), 6 with generalized
morphea (GenM), 3 with eosinophilic fasciitis (EF), and
1 with pansclerotic morphea. There were 5 cases of
mixed morphea (2 CM and LiScl, 1 with facial LiScl and
GM, 2 with EF and linear lesions). Eight subjects had
new lesions at time of enrollment. Features of active
lesions included extension of existing lesions (13),
warmth (13), erythematous/violacious color (13), and
skin induration at lesion perimeter (10). Damage
included subcutaneous atrophy (36), hyperpigmentation
(35), dermal atrophy (31), hypopigmentation (19), hair
loss (17), muscle atrophy (13), joint contracture (10),
limb shortening (5), and hemifacial atrophy(1). Only
three patients had extracutaneous manifestations,
including two with arthritis. ANA positivity was found
in 45% of tested patients, otherwise there were no con-
sistent laboratory or imaging abnormalities. Table 1.
Mean physician global assessment was 1.61 (range 0-
8) and mean CHAQ score was 0.19 (0-1.13). On a visual
analog scale (0-10), mean parent/subject score of overall
well-being was 1.80 (± 1.66) and pain was 1.41 (±2.03).
Health related quality of life was reported as excellent in
13, very good in 22, good in 7, and poor in 2 subjects.
A worst ever and current ACR functional class > I was
reported in 33% and 20.5%, respectively. Medications
used are listed in table 2.
Conclusion
jLS is reported more frequently in females and Cauca-
sians in the CARRA Registry. LiScl is the most common
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Table 1
Antinuclear
antibody
Elevated
IgG
Eosinophilia Abnormal
aldolase
Abnormal creatine
kinase
Abnormal CNS
imaging
Abnormal GI
study
Positive 14 6 5 3 1 1 3
Negative 17 20 30 16 24 10 3
Unknown 13 16 7 23 17 32 36
Total 44 42 42 42 42 43 42
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lesion subtype, representing 77% of all patients. 45% of
the jLS cohort is ANA positive. Subcutaneous and oral
MTX, MMF, and pulse CS are the most common medi-
cations used for treatment. There is an almost 2 year
delay in referral to pediatric rheumatology. There is sig-
nificant morbidity associated with jLS with 30% report-
ing limitation in functional capacity.
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Table 2
Oral methotrexate Subcutaneous methotrexate Mycophenolate mofetil Intravenous corticosteroids Longterm daily corticosteroids
Subjects (%) 21/42 (50%) 15/42 (36%) 15/42 (36%) 28-36 (78%) 17/35 (49%)
Current use 12 4 4 5 5
Past use 9 11 11 23 12
Wu et al. Pediatric Rheumatology 2012, 10(Suppl 1):A71
http://www.ped-rheum.com/content/10/S1/A71
Page 2 of 2
